Real-World Data Support Boston Scientific’s Personalized Spinal Cord Stimulation Therapy
Results of the PRO study of Boston Scientific’s Spectra WaveWriter spinal cord stimulator support the development of “all-in-one” spinal cord stimulation technology that delivers multiple waveforms and anatomical targeting for treating low back and/or leg pain.
You may also be interested in...
NANS 2020: Boston Scientific Expects Neuromodulation Business Rebound In 2020
At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.
Medtronic And Boston Scientific Finance Saluda's Neuromodulation System
Saluda Medical has secured funds from Medtronic and Boston Scientific to support the development of its spinal cord stimulation system for pain management.
Market Intel: NANS 2018: Positive Data Intensifies Spinal-Cord Stim's Big-Four Rivalry
The market for spinal cord stimulation (SCS) systems, used for treating chronic debilitating pain, is expanding relentlessly, and companies like Abbott Laboratories, Medtronic, Boston Scientific and Nevro are all vying to gain more market share with their respective technologies. At this year's annual meeting of the North American Neuromodulation Society (NANS) in Las Vegas, physicians were presented with the latest clinical evidence backing these innovations. This article looks at the overall SCS market, discusses study findings presented at NANS and the latest innovations. It also provides insights from two established pain management specialists on factors they think will drive SCS technologies forward.